Electroconvulsive Therapy, Ketamine, and Esketamine in a Patient with Major Depressive Disorder and Multiple Comorbidities: A Case Report over 10-year Treatment from Adolescence to Adulthood.
Keming Gao, Buket Koparal, Evrim Bayrak Oruc, Margret A Musso
{"title":"Electroconvulsive Therapy, Ketamine, and Esketamine in a Patient with Major Depressive Disorder and Multiple Comorbidities: A Case Report over 10-year Treatment from Adolescence to Adulthood.","authors":"Keming Gao, Buket Koparal, Evrim Bayrak Oruc, Margret A Musso","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>In this case report, we present a patient with treatment-resistant depression (TRD) and comorbid generalized anxiety disorder, eating disorder, post-traumatic stress disorder, and borderline personality disorder. Over a 10-year period, our case transitioned from adolescence to adulthood and received antidepressant monotherapy, adjunctive therapy with antipsychotics, lithium, or lamotrigine, several series of electroconvulsive therapy (ECT), ketamine infusion (KET-IFU), compounded ketamine intranasal spray (COM-KET), and intranasal esketamine (ESK). She had seventeen documented hospitalizations, five self-reported hospitalizations, three intensive outpatient program treatments, two partial hospitalization program treatments, and three residential treatments. She attempted suicide seven times. She received five acute ECT series, one series of KET-IFU, one series of acute ESK with weekly ECT, a series of COM-KET treatment for more than two years, and a series of ESK for more than two years. The patient had some short-term benefit from ECT and KET-IFU. However, she had two-years stability with COM-KET or ESK at two different times. She has been relatively stable without hospitalization or suicide attempt with ESK for more than two years, suggesting that patients with TRD with complex representations may benefit from ketamine treatment at different times of life development.</p>","PeriodicalId":94351,"journal":{"name":"Psychopharmacology bulletin","volume":"55 3","pages":"44-55"},"PeriodicalIF":0.0000,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11983475/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Psychopharmacology bulletin","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
In this case report, we present a patient with treatment-resistant depression (TRD) and comorbid generalized anxiety disorder, eating disorder, post-traumatic stress disorder, and borderline personality disorder. Over a 10-year period, our case transitioned from adolescence to adulthood and received antidepressant monotherapy, adjunctive therapy with antipsychotics, lithium, or lamotrigine, several series of electroconvulsive therapy (ECT), ketamine infusion (KET-IFU), compounded ketamine intranasal spray (COM-KET), and intranasal esketamine (ESK). She had seventeen documented hospitalizations, five self-reported hospitalizations, three intensive outpatient program treatments, two partial hospitalization program treatments, and three residential treatments. She attempted suicide seven times. She received five acute ECT series, one series of KET-IFU, one series of acute ESK with weekly ECT, a series of COM-KET treatment for more than two years, and a series of ESK for more than two years. The patient had some short-term benefit from ECT and KET-IFU. However, she had two-years stability with COM-KET or ESK at two different times. She has been relatively stable without hospitalization or suicide attempt with ESK for more than two years, suggesting that patients with TRD with complex representations may benefit from ketamine treatment at different times of life development.
在本病例报告中,我们报告了一位患有难治性抑郁症(TRD)并伴有广泛性焦虑症、饮食失调、创伤后应激障碍和边缘型人格障碍的患者。在10年的时间里,我们的病例从青春期过渡到成年期,接受了抗抑郁单药治疗,抗精神病药物,锂或拉莫三嗪的辅助治疗,几个系列的电休克治疗(ECT),氯胺酮输注(KET-IFU),复合氯胺酮鼻内喷雾剂(COM-KET)和鼻内艾氯胺酮(ESK)。她有17次记录在案的住院治疗,5次自我报告的住院治疗,3次强化门诊治疗,2次部分住院治疗,3次住院治疗。她曾七次试图自杀。患者接受5个急性ECT系列,1个KET-IFU系列,1个急性ESK系列,每周ECT, comm - ket系列治疗2年多,ESK系列治疗2年多。患者从ECT和KET-IFU中获得了一些短期的益处。然而,她在两个不同的时间用COM-KET或ESK稳定了两年。患者病情相对稳定,两年多来没有因ESK住院或自杀企图,提示具有复杂症状的TRD患者可能在生命发育的不同时期受益于氯胺酮治疗。